Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) - Total Assets
Based on the latest financial reports, Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) holds total assets worth CN¥1.91 Billion CNY (≈ $279.37 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Cheng Du Sheng Nuo Biotec Co. Ltd. A investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Cheng Du Sheng Nuo Biotec Co. Ltd. A - Total Assets Trend (2017–2024)
This chart illustrates how Cheng Du Sheng Nuo Biotec Co. Ltd. A's total assets have evolved over time, based on quarterly financial data. Check 688117 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Cheng Du Sheng Nuo Biotec Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2024)
Cheng Du Sheng Nuo Biotec Co. Ltd. A's total assets of CN¥1.91 Billion consist of 43.6% current assets and 56.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 13.3% |
| Accounts Receivable | CN¥133.17 Million | 8.1% |
| Inventory | CN¥304.75 Million | 18.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥52.98 Million | 3.2% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Cheng Du Sheng Nuo Biotec Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Cheng Du Sheng Nuo Biotec Co. Ltd. A market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cheng Du Sheng Nuo Biotec Co. Ltd. A's current assets represent 43.6% of total assets in 2024, a decrease from 46.8% in 2017.
- Cash Position: Cash and equivalents constituted 13.3% of total assets in 2024, up from 10.5% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 6.0% in 2017.
- Asset Diversification: The largest asset category is inventory at 18.5% of total assets.
Cheng Du Sheng Nuo Biotec Co. Ltd. A Competitors by Total Assets
Key competitors of Cheng Du Sheng Nuo Biotec Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.25 Billion |
|
Eris Lifesciences Limited
NSE:ERIS
|
India | Rs71.60 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥13.81 Billion |
|
Lotus Pharmaceutical Co Ltd
TW:1795
|
Taiwan | NT$106.15 Billion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC
|
India | Rs3.22 Billion |
Cheng Du Sheng Nuo Biotec Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.46 | 1.39 | 2.32 |
| Quick Ratio | 0.90 | 0.85 | 1.70 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥271.28 Million | CN¥184.03 Million | CN¥191.07 Million |
Cheng Du Sheng Nuo Biotec Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Cheng Du Sheng Nuo Biotec Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.90 |
| Latest Market Cap to Assets Ratio | 0.33 |
| Asset Growth Rate (YoY) | 25.2% |
| Total Assets | CN¥1.65 Billion |
| Market Capitalization | $546.28 Million USD |
Valuation Analysis
Below Book Valuation: The market values Cheng Du Sheng Nuo Biotec Co. Ltd. A's assets below their book value (0.33x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Cheng Du Sheng Nuo Biotec Co. Ltd. A's assets grew by 25.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Cheng Du Sheng Nuo Biotec Co. Ltd. A (2017–2024)
The table below shows the annual total assets of Cheng Du Sheng Nuo Biotec Co. Ltd. A from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.65 Billion ≈ $241.14 Million |
+25.25% |
| 2023-12-31 | CN¥1.32 Billion ≈ $192.53 Million |
+18.75% |
| 2022-12-31 | CN¥1.11 Billion ≈ $162.14 Million |
+15.83% |
| 2021-12-31 | CN¥956.62 Million ≈ $139.98 Million |
+61.32% |
| 2020-12-31 | CN¥592.98 Million ≈ $86.77 Million |
+14.27% |
| 2019-12-31 | CN¥518.92 Million ≈ $75.93 Million |
+8.50% |
| 2018-12-31 | CN¥478.25 Million ≈ $69.98 Million |
+37.35% |
| 2017-12-31 | CN¥348.20 Million ≈ $50.95 Million |
-- |
About Cheng Du Sheng Nuo Biotec Co. Ltd. A
ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company offers semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide,… Read more